U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT07465276) titled 'Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC' on March 06.
Brief Summary: This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC).
The names of the study drugs used in this research study are:
* ficerafusp alfa (a type of bifunctional antibody and recombinant fusion protein)
* pembrolizumab (a type of monoclonal antibody)
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Head and Ne...